Department of Neurology, Odense University Hospital, Odense, Denmark.
Br J Cancer. 2013 Mar 19;108(5):1189-94. doi: 10.1038/bjc.2013.87. Epub 2013 Feb 28.
Few studies have examined the association between use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and risk of glioma and the results have been equivocal. We therefore investigated the influence of NSAID use on glioma risk in a nationwide setting.
We used national registries in Denmark to identify all patients aged 20-85 years with a first diagnosis of histologically verified glioma during 2000-2009. Each case was matched on birth year and sex to eight population controls using risk-set sampling. We used prescription data to assess NSAID use and classified exposure to low-dose aspirin or non-aspirin (NA) NSAIDs into ever use or long-term use, defined as continuous use for 5 years. Conditional logistic regression was used to compute odds ratios (ORs), with 95% confidence intervals (CIs), for glioma associated with NSAID use, adjusted for potential confounders.
A total of 2688 glioma cases and 18,848 population controls were included in the study. Ever use of low-dose aspirin (OR=0.90; 95% CI: 0.77-1.04) or NA-NSAIDs (OR=1.05; 95% CI: 0.96-1.14) was not associated with glioma risk. Compared with never use, long-term use of low-dose aspirin or of NA-NSAIDs was associated with ORs of 0.80 (95% CI: 0.53-1.21) and 1.11 (0.57-2.17), respectively. We observed no clear patterns of risk in stratified analysis according to estimated doses of low-dose aspirin (≤ 100 mg, 150 mg).
We did not find any apparent association between aspirin or NA-NSAID use and risk of glioma, although our results may be consistent with a slight reduction in glioma risk with long-term use of low-dose aspirin.
很少有研究探讨阿司匹林或其他非甾体抗炎药（NSAIDs）的使用与胶质瘤风险之间的关系，结果也存在分歧。因此，我们在全国范围内调查了 NSAIDs 使用对胶质瘤风险的影响。
我们使用丹麦的国家登记处，确定了 2000-2009 年间所有首次诊断为组织学证实的胶质瘤的年龄在 20-85 岁的患者。每个病例都通过风险集抽样按出生年份和性别与 8 名人群对照相匹配。我们使用处方数据评估 NSAIDs 的使用情况，并将低剂量阿司匹林或非阿司匹林（NA）NSAIDs 的暴露情况分为曾经使用或长期使用，定义为连续使用 5 年。使用条件逻辑回归计算与 NSAIDs 使用相关的胶质瘤的比值比（OR），置信区间（CI）为 95%。
共纳入 2688 例胶质瘤病例和 18848 名人群对照。曾经使用低剂量阿司匹林（OR=0.90；95%CI：0.77-1.04）或非阿司匹林 NSAIDs（OR=1.05；95%CI：0.96-1.14）与胶质瘤风险无关。与从未使用相比，长期使用低剂量阿司匹林或非阿司匹林 NSAIDs 与 OR 分别为 0.80（95%CI：0.53-1.21）和 1.11（0.57-2.17）相关。根据低剂量阿司匹林（≤100mg，150mg）的估计剂量进行分层分析时，我们未观察到明显的风险模式。
我们没有发现阿司匹林或非阿司匹林 NSAIDs 使用与胶质瘤风险之间存在任何明显关联，尽管我们的结果可能与长期使用低剂量阿司匹林略微降低胶质瘤风险一致。
